T. Cameron

发表

Clinical benefit of erlotinib in male smokers with squamous-cell NSCLC.

G. Clark, A. D. Das Gupta, T. Cameron, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Single-agent paclitaxel in patients with previously untreated stage IV epithelial ovarian cancer. London Gynaecological Oncology and North Thames Gynaecological Oncology Groups.

M. Gore, J. Ledermann, G. Rustin, 1997, British Journal of Cancer.

Comparative Patient-reported Quality of Life (QOL) During Radiation Therapy (RT) in Patients Receiving Definitive RT Versus Postprostatectomy RT for Prostate Cancer

Ronald C. Chen, L. G. Hoffman, Andrew Z. Wang, 2012 .

Population Pharmacokinetic Modeling of Lucitanib in Patients with Advanced Cancer

M. Liao, M. Sale, Jim J. Xiao, 2022, European Journal of Drug Metabolism and Pharmacokinetics.

Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum‐based regimen and disease at baseline on efficacy and safety

A. Oza, J. Ledermann, E. Swisher, 2021, Cancer medicine.

Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma

A. Oza, J. Ledermann, D. Cella, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.

A. Oza, J. Ledermann, E. Swisher, 2020, The Lancet. Oncology.

3 Postprogression efficacy outcomes from the phase 3 ARIEL3 study of rucaparib in patients with platinum-sensitive recurrent ovarian carcinoma associated with either BRCA1 or BRCA2 mutations

A. Oza, J. Ledermann, E. Swisher, 2020 .

Integrated safety analysis of the poly (ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings

A. Tinker, A. Oza, J. Ledermann, 2019, Annals of Oncology.

Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety

A. Oza, Y. Drew, J. Ledermann, 2019, International Journal of Gynecological Cancer.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

James X. Sun, A. Oza, D. Provencher, 2017, The Lancet.

Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)

James X. Sun, A. Oza, J. Ledermann, 2018, Metabolic Changes in Ovarian Cancer.

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity.

H. Groen, E. D. de Vries, J. Verweij, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

LBA40_PRARIEL3: A phase 3, randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma (OC)

James X. Sun, A. Oza, J. Ledermann, 2017 .

Postprogression outcomes in patients with ovarian carcinoma associated with a mutation in a non-BRCA homologous recombination repair gene receiving rucaparib maintenance treatment: Results from the phase III study ARIEL3

A. Oza, J. Ledermann, E. Swisher, 2020 .

Comment on: “Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States”

S. Goble, K. Wallace, L. Maloney, 2019, PharmacoEconomics.

The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma

A. Oza, J. Ledermann, E. Swisher, 2020, Gynecologic Oncology.

Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group.

Christopher Poole, Tien Le, Susan Ellard, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3

A. Oza, J. Ledermann, E. Swisher, 2021, International Journal of Gynecological Cancer.

LIO-1: Initial phase 2 experience of lucitanib + nivolumab in patients with metastatic or recurrent cervical cancer (NCT04042116; ENGOT-GYN3/AGO/LIO) (034)

S. Pignata, N. Concin, C. Marth, 2022, Gynecologic Oncology.

The effect of age on efficacy and safety outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase III, randomized, placebo-controlled maintenance study in patients with recurrent ovarian carcinoma

R. L. Coleman, A. Oza, J. Ledermann, 2019, Gynecologic Oncology.